- Home
- MYGN vs VZIO Comparison
MYGN vs VZIO Comparison
Compare MYGN & VZIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- VZIO
- Stock Information
- Founded
- MYGN 1991
- VZIO 2002
- Country
- MYGN United States
- VZIO United States
- Employees
- MYGN N/A
- VZIO N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- VZIO Consumer Electronics/Appliances
- Sector
- MYGN Health Care
- VZIO Consumer Staples
- Exchange
- MYGN Nasdaq
- VZIO Nasdaq
- Market Cap
- MYGN 2.2B
- VZIO 2.3B
- IPO Year
- MYGN 1995
- VZIO 2021
- Fundamental
- Price
- MYGN $26.43
- VZIO $11.25
- Analyst Decision
- MYGN Buy
- VZIO Hold
- Analyst Count
- MYGN 12
- VZIO 9
- Target Price
- MYGN $28.18
- VZIO $10.75
- AVG Volume (30 Days)
- MYGN 651.3K
- VZIO 2.0M
- Earning Date
- MYGN 11-04-2024
- VZIO 11-07-2024
- Dividend Yield
- MYGN N/A
- VZIO N/A
- EPS Growth
- MYGN N/A
- VZIO 57.67
- EPS
- MYGN N/A
- VZIO 0.08
- Revenue
- MYGN $802,200,000.00
- VZIO $1,719,900,000.00
- Revenue This Year
- MYGN $13.84
- VZIO $8.45
- Revenue Next Year
- MYGN $9.57
- VZIO $9.82
- P/E Ratio
- MYGN N/A
- VZIO $148.41
- Revenue Growth
- MYGN 14.78
- VZIO 0.01
- 52 Week Low
- MYGN $13.82
- VZIO $4.82
- 52 Week High
- MYGN $29.30
- VZIO $11.30
- Technical
- Relative Strength Index (RSI)
- MYGN 44.56
- VZIO 56.61
- Support Level
- MYGN $25.90
- VZIO $11.13
- Resistance Level
- MYGN $27.55
- VZIO $11.26
- Average True Range (ATR)
- MYGN 0.88
- VZIO 0.08
- MACD
- MYGN -0.07
- VZIO -0.00
- Stochastic Oscillator
- MYGN 15.59
- VZIO 78.94
About MYGN Myriad Genetics Inc.
Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.
About VZIO VIZIO Holding Corp.
VIZIO Holding Corp operates two distinct integrated businesses: Device and Platform+. Through Device business, it offers a range of high-performance Smart TVs designed to address specific consumer preferences, as well as a portfolio of soundbars that deliver immersive audio experiences. It generates revenue from the shipment of these devices to retailers and distributors across the United States, as well as directly to consumers through the website. The Company's reportable segments: Device, and Platform+T. It derives maximum revenue from Device Segment.